CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
DNA-TRAP aims to develop a new class of antibacterial therapies using oligonucleotide therapeutics to combat drug-resistant infections. The project focuses on innovative drug delivery systems and fostering collaboration between industry and academia.
Antimicrobial agents, such as antibiotics, have dramatically reduced the number of deaths from infectious diseases over the last 70 years.
However, through overuse and misuse of these agents, many micro-organisms have developed antimicrobial resistance.
Oligonucleotide therapeutics have the potential to become the new class of antibacterials capable of treating a broad range of infections.
By acting on novel targets, they circumvent current resistance mechanisms and with judicious use, can suppr…
UNIVERSITY OF EAST ANGLIA
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, NORWICH
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Italy, Torino
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, LONDON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
